CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its second quarter 2016 investor update conference call and webcast at
4:30 p.m. Eastern Time on Thursday, August 4, 2016. Individuals
interested in participating in the call should dial (877) 643-7155 (U.S.
and Canada) or (914) 495-8552 (international) using conference ID number
49646361. To access the webcast, please visit the Investors section of
Ironwood's website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
The call will be available for replay via telephone starting August 4,
2016 at approximately 7:30 p.m. Eastern Time, running through 11:59 p.m.
Eastern Time on August 11, 2016. To listen to the replay, dial (855)
859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 49646361. The archived webcast will be available on
Ironwood's website for 14 days beginning approximately one hour after
the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating
medicines that make a difference for patients, building value for our
fellow shareholders, and empowering our passionate team. We are
advancing a pipeline of innovative medicines in areas of significant
unmet need, including irritable bowel syndrome with constipation
(IBS-C)/chronic idiopathic constipation (CIC), refractory
gastroesophageal reflux disease, uncontrolled gout, and vascular and
fibrotic diseases. We discovered, developed and are commercializing
linaclotide, the U.S. branded prescription market leader in the
IBS-C/CIC category, and we are applying our proven R&D and commercial
capabilities to advance multiple internally-developed and
externally-accessed product opportunities. Ironwood was founded in 1998
and is headquartered in Cambridge, Mass. For more information, please
visitwww.ironwoodpharma.com or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160721006328/en/
